|Bid||7,793.00 x 0|
|Ask||7,796.00 x 0|
|Day's range||7,766.00 - 7,906.00|
|52-week range||5,871.00 - 10,120.00|
|Beta (5Y monthly)||0.22|
|PE ratio (TTM)||47.44|
|Earnings date||05 Nov 2020|
|Forward dividend & yield||2.16 (2.74%)|
|Ex-dividend date||13 Aug 2020|
|1y target est||78.83|
Motley Fool contributor Jay Yao writes why he's looking at FTSE 100 component AstraZeneca as a great long-term investment. The post Why I’m thinking of AstraZeneca as a great long-term buy appeared first on The Motley Fool UK.
Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results
AstraZeneca said it would sell rights for its heart failure and blood pressure medicines Atacand and Atacand Plus to Germany's Cheplapharm Arzneimittel GmbH. AstraZeneca, which is among the front-runners in the race to develop a vaccine for the novel coronavirus, has been trying to focus on its cancer drug portfolio in a bid to streamline its business. The agreement with Cheplapharm supports AstraZeneca's strategy of focusing on newer medicines in main therapy areas, the drugmaker said.